Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate

Journal article


Kendler, D. L., McClung, M. R., Freemantle, N., Lillestol, M., Moffett, A. H., Borenstein, J., Satram-Hoang, S., Yang, Y.-C., Kaur, P., Macarios, D. and Siddhanti, S.. (2011). Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporosis International. 22(6), pp. 1725 - 1735. https://doi.org/10.1007/s00198-010-1378-z
AuthorsKendler, D. L., McClung, M. R., Freemantle, N., Lillestol, M., Moffett, A. H., Borenstein, J., Satram-Hoang, S., Yang, Y.-C., Kaur, P., Macarios, D. and Siddhanti, S.
Abstract

In this study, 250 women with osteoporosis were randomized to 12 months with subcutaneous denosumab 60 mg every 6 months or oral alendronate 70 mg once weekly, then crossed over to the other treatment. The primary endpoint, treatment adherence at 12 months, was 76.6% for alendronate and 87.3% for denosumab.

Keywordsadherence; alendronate; compliance; denosumab; persistence
Year2011
JournalOsteoporosis International
Journal citation22 (6), pp. 1725 - 1735
PublisherSpringer UK
ISSN0937-941X
Digital Object Identifier (DOI)https://doi.org/10.1007/s00198-010-1378-z
Scopus EID2-s2.0-79952673181
Page range1725 - 1735
Research GroupInstitute for Health and Ageing
Publisher's version
File Access Level
Controlled
Place of publicationUnited Kingdom
Permalink -

https://acuresearchbank.acu.edu.au/item/85225/adherence-preference-and-satisfaction-of-postmenopausal-women-taking-denosumab-or-alendronate

Restricted files

Publisher's version

  • 70
    total views
  • 0
    total downloads
  • 2
    views this month
  • 0
    downloads this month
These values are for the period from 19th October 2020, when this repository was created.

Export as